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A B S T R A C T
Introduction: The incidence of ischemic heart disease is higher in patients with HIV/AIDS. 
However, the frequency of angina pectoris in these patients is still not known. Literature about 
this subject is still scarce. 
Objective: To evaluate the prevalence of angina pectoris and risk factors for coronary disease 
and to examine the association between traditional risk factors and HIV-related risk factors 
and angina pectoris. 
Method: An epidemiological cross-sectional study, analyzed as case-control study, involving 584 
patients with HIV/AIDS. Angina pectoris was identified by Rose questionnaire, classified as 
definite or possible. Information regarding risk factors was obtained through a questionnaire, 
biochemical laboratory tests, medical records and anthropometric measures taken during 
consultations at AIDS treatment clinics in Pernambuco, Brazil, from June 2007 to February 2008. 
To adjust the effect of each factor in relation to others, multiple logistic regression was used. 
Results: There was a preponderance of men (63.2%); mean ages were 39.8 years for men, 
36.8 years for women. The prevalence of definite and possible angina were 11% and 9.4%, 
respectively, totaling 20.4%, with independent associations between angina and smoking 
(OR = 2.88; 95% CI: 1.69-4.90), obesity (OR = 1.62; 95% CI: 0.97-2.70), family history of heart 
attack (OR = 1.70; 95% CI: 1.00-2.88), low schooling (OR = 2.11; 95% CI: 1.24-3.59), and low 
monthly income (OR = 2.93; 95% CI: 1.18-7.22), even after adjustment for age.
Conclusion: This study suggests that angina pectoris is underdiagnosed, even in patients 
with medical monitoring, revealing lost opportunities in identification and prevention of 
cardiovascular morbidity.
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Introduction
The knowledge that human immunodeficiency virus (HIV) 
infection could harm the heart goes back to 1983 when the first 
case of cardiac Kaposi’s sarcoma was described.¹ Since then, 
a number of studies have identified the relationship between 
heart disease and AIDS in adults and this association is being 
increasingly reported as a cause of death.2
In 1996, with the introduction of highly active antiretroviral 
therapy (HAART), with the resulting reduction of morbidity 
and mortality and improvement of quality of life of HIV-
infected subjects,3 the description of atherosclerotic 
cardiovascular alterations4 became increasingly frequent in 
prospective studies. In this connection, a reduction in the 
frequency of heart alterations caused by opportunistic agents 
has been reported as well as an increase in atherosclerotic 
coronary events in patients with HIV/AIDS.5,6 The action of 
HIV itself,7 exposure to traditional risk factors for coronary 
heart disease (CHD),8 and the adverse effects of antiretroviral 
drugs in the cardiovascular system9-12 have all been suggested 
as the determining factors in these atherosclerotic alterations.
In a 3-year observational study with a cohort of 900-infected 
subjects, a fourfold incidence of myocardial infarction (MI) 
in HIV-positive patients treated with protease inhibitors (PI) 
was detected.13 On the other hand, some studies suggest the 
participation of non-PI antiretrovirals [reverse transcriptase 
inhibitors analogous to nucleosides (NRTI)] in the common 
metabolic alterations among HIV/AIDS subjects, said to result 
in cardiovascular disease.14 
An increase in coronary events has also been observed in 
infected populations that have never used antiretrovirals, 
suggesting a direct effect of the virus itself on the atherogenic 
process7 and/or individual exposure to smoking, hypertension, 
diabetes mellitus, dyslipidemia and traditionally recognized 
risk factors associated with the development of coronary 
atherosclerosis.15
However, despite the above mentioned, the association 
of risk factors with atherosclerotic ischemic cardiopathy in 
these patients is still controversial. With this in mind, the 
present study was carried out with the aim of establishing 
the prevalence of angina pectoris as a clinical manifestation of 
ischemic heart disease and the risk factors associated with its 
appearance in a HIV-infected population, seen at two reference 
hospitals for HIV/AIDS treatment in Pernambuco, Brazil. 
The following potential risk factors for CHD were analyzed: 
time elapsed since diagnosis of HIV/AIDS infection, use and 
type of antiretroviral regimen, CD4 lymphocyte count and the 
commonly known risk factors. 
Methods
A cross-sectional study, analyzed as a case-control, was 
conducted  from June 2007 to February 2008 involving 584 
HIV-infected patients aged over 20 years treated at two 
hospitals (Hospital Universitário Oswaldo Cruz and Hospital 
Estadual Correia Picanço) in Recife, Pernambuco, Brazil; both 
are reference centers for the treatment of AIDS. Subjects 
reporting acute or chronic CHD, myocardial infarction 
or revascularization surgery at any time before the HIV-
infection/AIDS diagnosis, and patients with signs of active 
AIDS or hospitalization in the previous three months of the 
study were excluded.
The frequencies of angina pectoris and risk fac-
tors for CHD were studied, as well as the association 
between angina pectoris and traditional risk factors for 
CHD [sex, age, ethnicity, sedentarism (< 4 times a week, 
30’  minimum),  monthly income (minimum wage) , 
schooling (studied years), alcohol use (classified accord-
ing to a specific questionnaire), smoking (all patients 
who declared themselves as smokers, regardless of the 
amount of smoked cigarettes), family history of CHD – 
sudden death and heart attack –, obesity [body mass 
index (BMI) > 25 kg/m²], central obesity (> 102 cm for men, 
and > 88 cm for women), arterial hypertension (systolic 
BP > 140 mmHg and diastolic BP > 90 mmHg), hypergly-
cemia (≥ 100 mg/dL), hypercholesterolemia (> 200 mg/dL), 
hypertriglyceridemia (≥ 150 mg/dL), low HDL (< 40 mg/dL) 
and high LDL cholesterol (> 130 mg/dL), time elapsed 
since diagnosis of HIV (< 24 and ≥ 24 months), use 
and type of antiretroviral regimen (with and without pro-
tease inhibitors) and CD4 lymphocyte count (< 350 and 
≥ 350 cells).
Patients with angina pectoris were those who presented 
definite or possible angina, as classified by Bodegard.16 In this 
classification, definite angina is the report of pain or discomfort 
located on the central or left chest region that occurs when 
walking fast or uphill, and making it necessary to stop or slow 
down, and disappears in less than 10 minutes after stoping 
the activity. Possible angina is considered when the patient 
reports pain or discomfort that occurs when walking fast or 
uphill but without accomplishing all the other requirements 
for definite angina. Identification of angina pectoris was made 
by means of the Rose questionnaire, accredited and adopted by 
the World Health Organization for this purpose,17 and the 
controls were those over the age of 20 who did not report chest 
pain or discomfort. 
Patients were selected from the HIV/AIDS outpatient clinics 
of the two hospitals (HUOC, HCP) at the time of their clinical 
consultation after agreeing to participate in this study by 
signing the free and informed consent form.
Risk factors information were obtained as follows: 
1) administration of a structured and encoded questionnaire 
designed to collect information on the presence of risk factors; 
2) assessment of blood glucose, triglycerides, total cholesterol 
and its HDL and LDL fractions, after a 12-hour fasting period; 
3) from the hospital records, CD4 lymphocyte count, use of 
antiretrovirals and type of regimen used; 4) anthropometrical 
measurements and blood pressure (mean diastolic and 
systolic measurements of the superior members taken two 
times during the consultation).
Considering an expected frequency of angina pectoris 
of 6.7% and also a plus or minus 2% margin of error with a 
95% confidence level, the sample size was estimated at 600 
individuals.
Time elapsed since HIV/AIDS diagnosis, the type of 
antiretroviral (ARV) regimen, smoking and obesity were 
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the items of comparison selected for their association with 
angina pectoris.
The data were stored in a specific database, following a 
review of the completed questionnaires, in order to avoid any 
information bias.
Odds ratios with 95% confidence intervals were used to 
measure the magnitude of the associations, using the statistical 
package STATA version 9.0. Multiple logistic regression was 
used to adjust the effect of each factor over the others.
The present study was approved by the Ethics in Research 
Committees (protocol number 052/05). 
Results 
The study comprised 584 HIV-infected patients, of whom 
369 (63.2%) were men with a mean age of 39.8 years (range, 
20 to 74 yr) and 215 (36.8%) women with a mean age of 36.8 
years (range, 20 to 67 yr). 
A total of 56.1% (325/579) of the patients reported low 
schooling (up to 8 years) and 81.2% (385/474) reported 
low income (less than two minimum wages) (1 minimum 
wage = US$ 194.87).
A history of heart attack and sudden death in first-degree 
relatives was reported in 164/549 (29.9%) and 76/519 (14.0%) 
patients, respectively.
Alcohol use was admitted by 239/557 (42.9%) patients, 
smoking by 140/583 (24.0%) and 358/582 (61.5%) were 
sedentary.
Overweight/obesity was present in 207/581 (35.6%) patients 
and only 113/584 (19.3%) presented central obesity. A total 
of 154/549 (26.7%) patients reported hypertension. Glucose 
levels in 87/575 (15.3%), triglyceride levels in 278/575 (48.3%), 
overall cholesterol in 167/575 (29.0%) and LDL in 102/541 
(18.8%) patients were increased. HDL levels were below the 
lower limit of normal in 517/575 (89.9%) of the patients.
In 393 subjects (67.4%) HIV infection had been diagnosed 
more than 24 months earlier (Table 1) and 467 (81.2%) were 
on ARV, of whom 256 (54.8%) were on a protease-inhibitor 
(PI) regimen and 211 (45.2%) were not, according to their 
medical records.
Of the total  sample population,  119/584 (20.4%) 
presented angina pectoris (65 definite – 11%, and 54 
possible – 9.4%), diagnosed by the Rose questionnaire. Of 
these, 95.8% were under 55 years old, 63.9% were black or 
mulatto, 37.9% reported smoking (45/119), 72.3% (86/119) 
had been diagnosed with HIV infection more than 24 
months earlier, and 77.1% (91/118) used ARV, of whom 
52.2% were on a PI-containing regimen and 47.7% were 
on no PI.
An independent association was found between angina 
pectoris and smoking (OR = 2.88; 95% CI: 1.69-4.90), 
obesity (OR = 1.62; 95% CI: 0.97-2.70), family history of heart 
attack (OR = 1.70; 95% CI: 1.00-2.88), and low schooling 
(OR = 2.11; 95% CI: 1.18-7.22) in the multivariate analysis, 
even after adjusting for age (Table 2). The variables used 
for this analysis were those with statistical significance 
in the univariate analysis – sex, smoking, low schooling, 
low monthly income, CD4 lymphocytes, ethnicity, alcohol 
use, family history of CHD/heart attack in first-degree 
relatives, obesity, low HDL, ARV use, and type of ARV 
regimen (Tables 1, 3 and 4).
Variables                                                                                          Pain                     No pain OR (95% CI) p
 n %  n %  n %   
Time elapsed since diagnosis 
 Up to 24 months 190 32.6 33 17.4 157 82.6 1
 > 24 months 393 67.4 86 21.9 307 78.1 1.33 (0.85-2.07) 0.206
ARV use
 No 109 18.8 27 24.8 82 75.2 1
 Yes 472 81.2 91 19.3 381 80.7 0.72 (0.44-1.18) 0.200*
ARV type
 Without ARV 109 18.9 27 24.8 82 75.2 1
 Without PI 211 36.7 43 20.4 168 79.6 0.77 (0.44-1.34) 0.368
 With PI 256 44.4 47 18.4 209 81.6 0.68 (0.40-1.17) 0.165*
CD4 level**
 > 350 cells/mm3 250 59.9 54 21.6 196 78.4 1
 < 350 cells/mm3 167 40.1 22 13.2 145 86.8 0.55 (0.32-0.94) 0.030*
*Multivariate analysis; **Brazilian Ministry of Health.27 
Table 1 - Frequency distribution and univariate analysis of the association between time elapsed since diagnosis, CD4 
lymphocyte level, use and type of ARV regimen with angina pectoris
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Variables   OR (95% CI)   p
Age 0.96 (0.94-0.99) 0.020
Schooling
 Less than 8 years 2.11 (1.24-3.59) 0.006
 More than 8 years 1.0 -
Smoking
 Smoker 2.88 (1.69-4.90) 0.000
 Non-smoker/ex-smoker 1.0 -
Monthly income
 Low (< 2x minimum wage) 2.93 (1.18-7.22) 0.019
 High (> 2x minimum wage) 1.0 -
Family history of CHD/attack
 Present 1.70 (1.01-2.88) 0.046
 Absent 1.0 -
Overweight/obesity
 Present 1.62 (0.97-2.70) 0.063
 Absent 1.0 -
*Sex, ethnicity, alcohol use, CD4 level, ARV use, type of ARV regimen and HDL have been 
omitted from the model. The model was adjusted for age.
Table 2 - Final multivariate model of the association between risk factors 
and angina pectoris
Variables                                                                                          Pain                     No pain OR (95% CI) p
 n %  n %  n %   
Sex
 Female 215 36.8 55 25.5 160 74.5 1
 Male 369 63.2 64 17.3 305 82.7 1.64 (1.09-2.46) 0.018†
Age
 20-54 yr 548 93.8 114 20.8 434 79.2 1
 > 55 yr 36 6.2 05 13.9 31 86.1 0.61 (0.23-1.61) 0.323
Schooling
 < 10 years 254 43.9 34 13.4 220 86.6 1
 > 10 years 325 56.1 84 25.8 241 74.1 2.25 (1.45-3.49) 0,000†
Monthly income
 > 2x minimum wage 89 18.8 06 6.7 83 93.3 1
 < 2x minimum wage 385 81.2 90 23.4 295 76.6 4.22 (1.78-9.98) 0.001†
Ethnicity
 White + Yellow + Indigenous 180 30.9 43 23.9 137 76.1 1
 Black + Brown 403 69.1 76 18.9 327 81.1 0.74 (0.48-1.13) 0.165†
Smoking
 Non-smoker 443 76.0 74 16.7 369 83.3 1
 Smoker 140 24.0 45 32.1 95 67.9 2.36 (1.53-3.64) 0.000†
Alcohol use
 Absent 318 57.1 57 17.9 261 82.1 1
 Present 239 42.9 55 23.0 184 77.0 1.36 (0.90-2.07) 0.139†
Table 3 - Frequency distribution and univariate analysis of the association between traditional risk factors* and angina 
pectoris
(Cont.)
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Variables                                                                                          Pain                       No pain OR (95% CI) p
 n %  n %  n %   
Overweight/obesity** BMI = [weight(kg)]/[h(m)]²
 Absent (≤ 25 kg/m²) 374 64.4 69 18.4 305 81.6 1
 Present (> 25 kg/m²) 207 35.6 49 23.7 158 76.3 1.37 (0.90-2.07) 0.135†
Central obesity**
 Absent (≤ 102 cm men; ≤ 80 cm women) 471 80.7 92 19.5 379 80.5 1
 Present (> 102 cm men; > 80 cm women) 113 19.4 27 23.9 86 76.1 1.29 (0.79-2.10) 0.302
Hypertension (JNC 7)28 
 Absent 425 73.4 88 20.7 337 79.3 1
 Present 154 26.6 30 19.5 124 80.5 0.92 (0.58-1.47) 0.746
Fasting glucose**
 Normal 480 84.7 94 19.6 386 80.4 1
 High 87 15.3 14 16.1 73 83.9 0.78 (0.42-1.45) 0.446
Cholesterol**
 Normal 408 71.0 81 19.8 327 80.2 1
 High 167 29.0 29 17.4 138 82.6 0.84 (0.53-1.35) 0.491
HDL-C**
 Normal 58 10.1 07 12.1 51 87.9 1
 Low 517 89.9 103 19.9 414 80.1 1.81 (0.79-4.11) 0.155†
LDL**
 Normal 439 81.1 81 18.4 358 81.6 1
 High 102 18.9 21 20.6 81 79.4 0.87 (0.57-1.35) 0.561
Triglycerides**
 Normal 297 51.6 62 20.9 235 79.1 1
 High 278 48.4 48 17.3 230 82.7 0.79 (0.52-1.20) 0.272
*Obesity, central obesity, arterial hypertension, glucose, overall cholesterol, triglycerides, HDL, LDL; †multivariate analysis; **NCEP-ATPIII.29 
Table 4 - Frequency distribution and univariate analysis of the association between traditional risk factors* and angina 
pectoris
Variables                                                                                          Pain                      No pain OR (95% CI) p
 n %  n %  n %   
Sedentarism
 Absent 224 38.5 45 20.0 179 800 1
 Present 358 61.5 73 20.4 285 79.6 1.01 (0.67-1.54) 0.930
Family history of CHD/death
 Absent 443 85.4 85 19.2 358 80.8 1
 Present 76 14.6 17 22.4 59 77.6 1.21 (0.67-2.18) 0.520
Family history of CHD/attack
 Absent 385 70.1 70 18.2 315 81.8 1
 Present 164 29.9 40 24.4 124 75.6 1.45 (0.93-2.25) 0.097†
*Sex, age, schooling, monthly income, ethnicity, smoking, alcohol use, sedentarism, family history of CHPD; †multivariate analysis.
Table 3 - Frequency distribution and univariate analysis of the association between traditional risk factors* and angina 
pectoris (cont.)
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Discussion
Although ischemic cardiovascular alterations in patients 
with AIDS have been exhaustively studied, in the review of 
the literature no studies were identified dealing specifically 
with stable angina in patients with AIDS, hence the 
exploratory nature of the present study. On the other hand, 
since the identification is based on the clinical history, 
the Rose questionnaire adopted by WHO17 was used for 
epidemiological reasons to identify angina pectoris. 
In our study,  the prevalence of definite angina 
pectoris (with all the typical symptoms) in HIV-infected 
patients was 11%, representing, for ischemic heart 
diseases (myocardial infarction and angina pectoris), 
a prevalence two and a half times higher than in the 
general Brazilian population (4.1%; 95% CI: 2.9-6.7), and 
three times greater than in the population of Recife (3.7%; 
95% CI: 2.1-5.2), identified by a home-based survey 
conducted in fifteen Brazilian capitals (2000-2003).18 It 
likewise represents almost twice the angina pectoris 
prevalence found in a major meta-analysis carried out by 
Hemingway19 comprising 74 studies, with a total population 
of 201,821 men and 199,494 women from 31 different 
countries. Among the latter, the prevalence of definite 
angina, diagnosed by the Rose questionnaire, was 6.7% for 
women and 5.7% for men. In our study, when the patients 
with possible angina (chest pain on exertion without 
fulfilling all the classical angina characteristics included in 
the Rose questionnaire) were added to the definite angina 
patients, this frequency rose to 20.4%. 
The inclusion of possible angina patients, as defined by 
Bodegard,16 is based on his important study that reported 
higher mortality from cardiovascular disease after 26 years 
of monitoring in patients diagnosed with angina by the 
Rose questionnaire, but who did not meet all the criteria 
for classical angina.
Our findings become even more significant when 
patients are analyzed by age: the mean age for our patients 
was 39.8 for men and 36.8 for women. In Hemingway’s 
meta-analysis19 the prevalence of angina in populations 
under 45 years of age was even lower, namely between 3.2 
and 3.8%. 
Finally, it is important to emphasize that none of our 
patients reported any specific cardiological complaint in 
the HIV/AIDS clinic or underwent any process of prior 
selection. In other words, none of them had been identified 
by their doctors as having angina pectoris, a situation that 
is true for many HIV/AIDS health services.
Regarding the traditional risk factors for CHD, it was 
found that smoking, overweight/obesity, a family history 
CHD in first-degree relatives, low schooling and low 
monthly income (< 2x minimum wage) all turned out 
as independent factors associated with a high risk of 
developing angina pectoris.
Smoking was the risk factor most strongly associated 
wi th  angina  pector is  among our  pat ients ,  more 
than tripling the chance of developing the condition 
(OR = 2.22; 95% CI: 1.37-3.58). Its frequency (24.0%) in the 
overall population of this study was similar to that found 
in the population of Recife (24.4%) (2000-2003 survey),18 
in general, and represented half the smoking frequency 
reported by Friis-Møller et al.20 in 17,852 AIDS patients studied 
at the DAD study (51.5%). Also, our results are in contrast to 
the findings of Neumann et al.,21 who reported 67% and 
52%, respectively, in homosexuals and heterosexuals, 
obtained in 309 infected patients. 
On the other hand, overweight/obesity (BMI ≥ 25 kg/
m2), present in 35.6% of the patients, represented a 62% 
increase in the chance of developing stable angina in the 
sample population (OR = 1.62), but central obesity was not 
statistically significant (frequency = 19.4%).
A family history of CHD/heart attack increased in 70% 
the risk of developing angina pectoris (OR = 1.70) in our 
patients, confirming the positive relationship between 
family history of CHD and coronary heart diseases in 
patients with AIDS, similar to the relation reported in the 
general population, as presented by Moraes and Souza.22
In addition, low schooling (up to 8 years) and low 
monthly income (≤ 2x US$ 194.87), respectively, doubled 
(OR = 2.11) and tripled (OR = 2.93) the risk of developing 
angina pectoris in the population studied. These results 
are similar to those found in other studies covering the 
overall Brazilian population (association between CHD and 
these risk factors). 
Unlike population-based studies which show that an 
increased glucose level (> 99 mg/dL), arterial hypertension 
(PAS ≥ 140 mmHg and/or PAD ≥ 90 mmHg) and sedentarism 
are associated with increased risk for CHD among men and 
women,23 in our study these factors were not associated 
with the development of angina pectoris. Increased levels 
of glucose, hypertension and sedentarism were found in 
15.3%, 26.6% and 61.5% of the subjects, respectively. 
Despite the many studies indicating the association 
between dyslipidemia and coronary events24 in the 
overall population and in the HIV-infected population, 
no associations between angina pectoris and hyper-
cholesterolemia (≥ 200 mg/dL), hypertrygliceridemia 
(≥ 150 mg/dL), high LDL (≥ 130 mg/dL) and low HDL (≤  45 mg/dL) 
were observed in our study.
Agreeing with Spósito et al.,25 who state that some lipid 
abnormalities are common in HIV patients, indicating that 
the infection itself change these profiles, we found a high 
frequency (90%) of low HDL-c. However we did not find 
similar results regarding LDL-C (19%) and triglycerides 
(50%).
Another important result to be emphasized is that, in the 
case of Pernambuco, despite the fact that the time elapsed 
since HIV diagnosis reflects the type of ARV regimen, since 
the majority of the patients who seek AIDS treatment at 
reference centers are at advanced stages of the disease, in 
our sample this variable was not associated with angina 
pectoris. Likewise, we did not find any positive association 
between ARV use and CD4 lymphocyte levels.
The prevalence of angina pectoris was 18.4% and 20.4% 
in patients receiving ARV with and without PI, respectively, 
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a difference not statistically significant, similarly to the 
findings of Coplan et al.,26 who found no significant 
differences in myocardial infarction rates between 
individuals receiving ARV with and without PI. 
In our study, it is important to point out that many 
patients had already used several types of ARV regimens 
(with and without PI), which prevent a correct evaluation 
of the association between the type of ARV regimen and 
the risk of developing angina pectoris.
Conclusion
The present study showed that around 20.4% of the patients 
with HIV/AIDS have a potential risk of ischemic coronary 
disease not identified by their doctors, despite their regular 
attendance at health services. Thus, simple and well-defined 
questions, such as the ones in the Rose questionnaire, 
might be useful in identifying this clinical condition and 
for selecting patients that need detailed cardiological 
investigation and referral to experts in this area.
Our results also corroborate the influence of the 
traditional risk factors (smoking, obesity, family history of 
heart attack) in the development of angina pectoris in HIV-
infected patients. 
From this perspective, our study not only presents a starting 
point for the identification of ischemic coronary disease in 
such patients but also, most importantly, points to the real 
possibility of including the constant and systematic monitoring 
of these patients as part of routine clinical work within the 
framework of an early preventive and therapeutic approach. 
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